Renal cell carcinoma: Bone metastases, immunotherapy and interleukin 6;Cancer du rein: Metastases osseuses, immunotherapie et interleukine 6

Annales de Medecine Interne

Volumn 150, Issue 5, 1999, Pages 388-393

  Paule, Bernard ^a   Clerc, Didier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Bone metastases; Immunotherapy; Interleukin 6; Renal cell carcinoma

Indexed keywords

ALPHA2 INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RETINOID; INTERLEUKIN 2; INTERLEUKIN 6 RECEPTOR; TRANSCRIPTION FACTOR;

BONE METASTASIS; IMMUNOTHERAPY; KIDNEY CARCINOMA; PATHOGENESIS; REVIEW; TUMOR GROWTH; ANIMAL; APOPTOSIS; BLOOD; BONE TUMOR; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY TUMOR; METASTASIS; MORTALITY; MOUSE; NUDE MOUSE; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TIME;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-6; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0033192161     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. PAGANO S, FRANZOLO F, DUGGERI P: Renal cell carcinoma metastases. Scand J Urol Nephrol, 1996; 30: 165-72.
2. DEKERNION JB, RAMMING KP, SMITH RB: The natural history of metastatic renal cell carcinoma. J Urol, 1978; 120: 148-52.
3. DARNELL JE Jr, KERR IM, STARK GR: STAT pathways and transcriptional activation in response to IFNs and other extra-cellular signaling proteins. Science, 1994; 264: 1415-21.
4. NAKAJIMA T, KINOSHITA S, SASAGAWA T et al.: Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL-6: Proc Nat Acad Sci USA, 1993; 90: 2207-11.
5. NISHIMURA R, MORIYAMA K, YASUKAWA K et al.: Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res, 1998; 13: 777-85.
6. TSUKAMOTO T, KUMAMOTO Y, MIYAO N et al. : Interleukin-6 in renal cell carcinoma. J Urol, 1992; 148: 1778-82.
7. MIKI S, IWANO M, MIKI Y et al.: IL-6 functions as an autocrine growth factor in renal carcinoma. FEBS Letter, 1989; 250: 607-10.
8. BLAY JY, BOLON J, ALBERTE I et al.: Growth inhibition of renal carcinoma cell lines by interleukin 6 antisense oligonucleotides: an internal autocrine loop. Proc AACR, 1994; 3557: Abst 35.
9. TANEKAWA J, YOSHIYUKI K, FUKIMOTO M et al.: Enhanced expression of interleukin-6 in primary human renal cell carcinoma. J Natl Cancer Inst, 1991; 83: 1668-72.
10. GRUSS HJ, BRACH MA, MERSTELMANN RH, HERRMANN F: Interferon-gamma interrupts autocrine growth mediated by endogenous interleukin-6 in renal cell carcinoma. Int J Cancer, 1991; 49: 770-2.
11. YONEDA T, NAKAI M, MORIYAMA K et al.: Neutralizing antibodies to human interleukin-6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res, 1993; 53: 737-40.
12. WEISGLAS M, SCHAMHART D, LOWICK C, PAPAPOULOS S, VOS P, KURTH KH: Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone-related peptide by a human renal cell carcinoma implanted into nude mice. J Urol, 1995; 153: 854-7.
13. WEISGLAS MG, SCHAMHART DHJ, CLEMENS WGM et al.: The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice. Endocrinology, 1997; 138: 1879-85.
14. PAULE B, CLERC D, RUDANT C et al.: Enhanced expression of interleukin-6 protein in bone and serum of metastatic renal cell carcinoma. Human Pathol, 1998; 29: 421-4.
15. BLAY JM, NEGRIER S, COMBARET V et al.: Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res, 1992; 52: 3317-22.
16. BLAY JY, PALLARDY M, RAVAUD A et al.: Serum IL-6, soluble gp80 IL-6 receptor and CRP in metastatic renal cell carcinoma (MRCC) treated with immunotherapy in the crecy trial: correlation to response. Ann Oncol, 1996; 7 (Suppl 5): Abstr 2540.
17. FOSSA SD, LIEN HH, LINDEGAARD M: Effect of recombinant interferon alfa on bone metastases of renal cell carcinoma. N Engl J Med, 1991; 324: 633-4.
18. NAMUS DM, BOGENRIEDER T, ENGEISTER D et al.: Analysis of retinoid receptors (RRAR) and retinoid-induced antiproliferative effects alone and in combination with interferon alfa in a human renal cancer. Aberrant RAR alfa transcript in a retinoid resistant cell line. Proc AACR, 1994; 507: Abst 35.
19. PELIGANO L, CHELBI-ALIX MK : L'interféron et l'acide rétinoïque dans le traitement des cancers humains : mécanismes d'action. Bull Cancer, 1998; 85: 313-8.
20. PAULE B, BRION N: Retinoids and metastatic renal cell carcinoma. Ann Med Interne, 1997; 148: 496-501.
21. MOTZER RJ, SCHWARTZ L, MURRAY LAW T: Interferon alfa-2a and 13-cis-retinoic acid renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol, 1995; 13: 1950-7.
22. OGATA A, NORIHIRO N, YOSHIHITO S et al.: Inhibitory effect of all trans retinoic acid on the growth of freshly isolated myeloma cell via interference with interleukin-6 signal transduction. Blood, 1994; 84: 3040-8.
23. PAULE B, BONHOMME-FAIVRE B, RUDANT E, FERRIERE F: Interferon alfa-2a plus tretinoin in patients with metastatic renal cell carcinoma. A pilot study. Am J Health-Syst Pharm, 1997; 54: 190-2.
24. SANESHIGE S, MANO H, TEZUKA K et al.: Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K OC-2. Bioch J, 1995; 309: 721-4.
25. KAJI H, SUGIMOTO T, KANATANI M, FUKASE M, KUMEGAWA M, CHIHARA K: Retinoic acid induces osteoclast-like cell formation by directly acting on hemopoietic blast cells and stimulates osteopontin mRNA expression in isolated osteoclasts. Life Sci, 1995; 56: 1903-13.
26. PHILLIPS JH, GEMIO BT, MYERS WN, RAYNER AA, LANIER L: In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined interleukin-2 and LAK cell therapy. J Clin Oncol, 1987; 5: 1933-41.
27. TRITARELLI E, ROCCU E, TESTA U et al.: Adoptive immunotherapy with high-dose interleukin-2 kinetics of circulating progenitors corelate with interleukin-6 and granulocyte colony stimulating factor. Blood, 1991; 74: 741-9.
28. TOSATO G, PIKE SA: Interferon-beta 2/ interleukin-6 is a co-stimulant for human T lymphocytes. J Immunol, 1988; 146: 1380-4.
29. LUGER TA et al.: IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol, 1989; 143: 1206-9.
30. MULE JJ, CUSTER MC, TRARS WD, ROSENBERG SA: Cellular mechanisms of the antitumoral activity of recombinant IL-6 in mice. J Immunol, 1992; 148: 2622-9.
31. KLINGEMANN H-G, WONG E: Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells. Cancer Immunol Immunother, 1991; 33: 395-7.
32. DOUGHERTY GJ, THACKER JD, LAVEY RS et al.: Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth factor in vivo. Cancer Immunol Immunother, 1994; 38: 339-45.
33. LEE TY, KOO AS, PEYRET C et al.: The effects of IL-6 on tumor infiltration lymphocytes derived from renal cell cancer. J Urol, 1991; 145: 663-7.
34. TANNER J, TOSATO G: Impairement of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest, 1996; 8: 239-47.
35. ZHOU D, MUNSTER A, WINCHURCH RA: Pathologic concentrations of interleukin-6 inhibe T cells responses via induction of activation of TGF-β. FASEB J, 1991; 5: 2582-5.
36. MCINTOSH JK, JABLONS DM, MULE JJ et al.: In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum IL-6 in tumor-bearing mice. J Immunol, 1989; 143: 162.
37. UTSMI J, TAKAI Y, YADA T et al.: Enhanced production of IL-6 in tumor bearing mice and determination of cells responsible for its augmented production. J Immunol, 1990; 145: 397-403.
38. RAVOET C, DE GREVE J, VADEWOUDE K et al.: Tumor stimulating effect of recombinant interleulin-6. Lancet, 1994; 304: 1576-7.
39. LU C, VICKERS MF, KERBEL RS: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA, 1992; 89: 9215-9.
40. GLEAVE ME, ELHILALU M, FRADET Y et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med, 1998; 338: 1265-71.
41. WONG LH, KRAVER KG, HATZINISIRIOU I et al.: Interferon-resistant human melanoma cells are deficient in ISGF3 components STAT1, STAT2 and p48-ISCF3 gamma. J Biol Chem, 1997; 272: 28779-85.
42. BARNES PJ, KARIN M: Nuclear Factor-KB. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336: 1066-71.
43. TAKENAWA J, KARIEKO Y, OKUMURA K et al.: Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinoma and effects on expression of interleukin-6 or interlekin-6 receptor. J Urol, 1995; 153: 858-62.
44. LECLAIR KP, BLANAR MA, SHARP PA: The p50 subunit of NF-KB associates with the NF-IL-6 transcription factor. Proc Nat Acad Sci USA, 1992; 83: 8145-9.
45. MATSUSAKA T, FUJIKAWA K, NISHIO Y et al.: Transcription factors NF-IL6 and NF-KB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci, 1993; 90: 10193-7.
46. BOURS V, DEJARDIN E, BONIZZI G et al.: Le facteur transcriptionel NF-KB : rôle au cours de l'oncogène et de la réponse au traitement anticancéreux. Med Sci, 1998; 14: 566-71.
47. LINDEMAN A, BROSSART P, HOFFKEN K et al.: Serum cytokine levels in cancer patients treated with different schedules of ultra-low dose interleukin-2. J Immunother, 1993; 15: 225-229.
48. MEFFERT M, HANNINEN EL, MENZEL T et al.: In vivo time and dose dependancy of interleukin-6 secretion in response to low dose subcutaneous recombinant interleukin 2. Cancer Biother, 1994; 9: 307-16.
49. JABLONS DM, MULE JJ, MCINTOSH JK et al.: IL-6 as a circulating hormone induction by cytokine administration in humans. J Immunol, 1989; 142: 1542-7.
50. TOREN A, NOVICK D, ACKERSSTEIN A, OR R, SLAVIN S, NAGLER A: Soluble IL-6 receptor (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-a or donor lymphocytes following bone marrow transplantation. Bone Marrow Transplant, 1996; 18: 721-4.
51. SCHAAFSMA MR, FALKENBURG JHF, LANDERGENT JE et al.: In vitro production of interleukin-5, granulocyte-macrophage colony stimulating factor, macrophage colony -stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood, 1991; 78: 1981-4.
52. GEMBO BT, PALLADINO Jr A, JAFFE HS, ESPEVIK TP, RAYRER AA: Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res, 1988; 48: 5864-7.
53. KOO AS, BOCHNER B, DE KERNION JB, BELLEDEGRUN A: Production and regulation of interleukin-6 by renal cell carcinoma : in vitro protein activity and mRNA gene expression. Urology, 1990; 41: 710-5.
54. JOURDAN M, ZHANG XG, PORTIER M, BOIRON JM, BATAILLE R, KLEIN B: IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol, 1991; 147: 4402-7.
55. TAMURA T, UDAGAWA N, TAKAHUSHI N et al.: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci, 1993; 90: 11924-8.
56. ROSE-JOHN S, HEINRICH PC: Soluble receptors for cytokines and growth factors. Generation and biological function. Biochem J, 1994; 300; 281-90.
57. ISCHIMI Y, MUJAURA C, JIN CH et al.: IL-6 is produced by osteoblasts and induce bone resorption. J Immunol, 1990; 145: 3297-303.
58. HURLEY MH, ABREU C, MARCELLO K et al.: Regulation on NFIL-6 and IL-6 expression by basic fibroblast growth factor in osteoblasts, J Bone Miner Res, 1996; 11: 760-7.
59. BARILLÉ S, COLLETTE M, BATAILLE R, AMIOT M: Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but down regulate of osteocalcin. Blood, 1995; 86: 3151-9.
60. CHAUHAN D, UCHIYAMA H, ARBARALI Y et al: Multiple myeloma adhesion-induced interleukin-6 expression in bone marrow stroma cells involves activation of NF-Kappa B. Blood, 1996; 87: 1104-12.
61. SINGH RK, BUCANA CD, GUTMAN M, FAN D, WILSON MR, FIDLER IJ: Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol, 1994; 145: 365-74.
62. SINGH RK, GUTMAN M, BUCANA CD, SANCHEZ R, LLANSA N, FIDLER IJ: Interferon alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci USA, 1995; 92: 4562-6.
63. BERSE B, BROWN LF, VAN DER WATER L et al.: Vascular permeability factor (VEGF) is expressed differentially in normal tissues, macrophages and tumors. Mol Cell Biol, 1992; 3: 211-20.
64. BROWN LF, BERSE B, JACKMAN RW et al.: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in kidney and bladder carcinomas. Am J Pathol, 1993; 143: 1255-62
65. MOTRO B, ILIN A, SACHS C, KESHET E: Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA, 1990; 87: 3092-6.
66. VARNER JA, CHERESH DA: Tumor angiogenesis and the role of vascular cell integrin αVβ3. In: De Vita Ed. Important advances in oncology. Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven, 1996; 69-87.
67. HUGHES DE, WRIGHT KR, ULY HL: Bisphosphonates promote apoptose in murine osteoclasts in vitro and in vivo. J Bone Miner Res, 1995; 10: 1478-87.
68. PASSERI G, GIRASOLE G, ULIETTE V et al.: Bisphosphonates inhibit IL-6 production by human osteoblastic cells MGC3. J Bone Miner Res, 1994; 9: suppl 1, S230.
69. SAVAGE AD, BELSON DJ, VESCIO RA, LICHTENSTEIN AK, BERENSON JR: Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood, 1996; 88: 105a, A409.
70. LISSONI P, CAZZANGA M, BARNI S et al.: Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumors patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer, 1997; 33: 304-6.
71. DEMARTIS A, BERNASSOLA F, SAVINO R et al.: Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res, 1996; 56: 4213-8.